Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term endothelin receptor blockade improves cardiovascular function in diabetes.

S Verma1, E Arikawa, J H McNeill

  • 1Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Canada.

American Journal of Hypertension
|July 24, 2001
PubMed
Summary

This study investigated whether blocking endothelin receptors could improve heart and blood vessel function in diabetic rats. Researchers used a rat model of diabetes and tested the effects of bosentan, a drug that blocks endothelin receptors. They found that diabetic rats had impaired heart function and exaggerated blood vessel contractions. Bosentan treatment improved heart function and normalized blood vessel responses. The study also showed increased endothelin-1 in diabetic tissues. These findings suggest that endothelin signaling contributes to diabetic cardiovascular dysfunction and that blocking these receptors may be a potential treatment strategy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of Olfactory Function on Appetite and Nutritional Status in the Elderly Requiring Nursing Care.

The journal of nutrition, health & aging·2020
Same author

Inhibition of matrix metalloproteinase-2 improves endothelial function and prevents hypertension in insulin-resistant rats.

British journal of pharmacology·2011
Same author

Endothelin-1 modulates angiotensin II in the development of hypertension in fructose-fed rats.

Molecular and cellular biochemistry·2009
Same author

Ovarian follicular and corpus luteum changes, progesterone concentrations, estrus and ovulation following estradiol benzoate/progesterone based treatment protocol in cross-bred cows.

Animal reproduction science·2006
Same author

The effects of vanadium treatment on bone in diabetic and non-diabetic rats.

Bone·2005
Same author

Alterations in the vascular actions of insulin in the pathogenesis of insulin resistance and hypertension.

Advances in experimental medicine and biology·2002

Area of Science:

  • Cardiovascular physiology in metabolic disorders
  • Pharmacological interventions in diabetes
  • Endothelin signaling in disease

Background:

Cardiovascular dysfunction is a common complication in diabetes, yet the specific mechanisms remain unclear. Prior research has shown that endothelin-1 (ET-1) contributes to vascular and cardiac impairments in various disease states. However, the role of ET-1 in diabetic cardiovascular dysfunction has not been fully established. No prior work had resolved whether ET receptor blockade could reverse these impairments in diabetic models. This gap motivated the current study to examine the effects of chronic ET receptor blockade in diabetic rats. Established knowledge includes the role of ET-1 in regulating vascular tone and cardiac function. This paper's contribution lies in linking ET-1 to diabetic cardiovascular complications and testing a potential therapeutic approach. The study focuses on a specific mechanism rather than general diabetic outcomes. It was already known that ET-1 influences vascular reactivity, but its role in diabetes remained uncertain.

Purpose Of The Study:

Keywords:
endothelin receptor blockadecardiovascular dysfunctiondiabetic ratsbosentan treatment

Frequently Asked Questions

Bosentan treatment improved heart function and normalized vascular reactivity in diabetic rats.

Heart function was assessed using ex vivo working hearts, measuring +dP/dt, -dP/dt, and LVDP.

To detect ET-1-like immunoreactivity in heart and vascular tissues of diabetic rats.

It suggests increased ET-1 signaling in diabetic tissues compared to controls.

Bosentan normalized exaggerated contractile responses to ET-1 in diabetic rats.

Related Experiment Videos

The aim of this study was to evaluate the effects of chronic endothelin receptor blockade on cardiovascular function in diabetic rats. The specific problem addressed is the potential contribution of endothelin-1 to diabetic cardiovascular complications. The motivation stems from the lack of clarity on whether ET-1 contributes to these complications and whether blocking its receptors could improve outcomes. This study tests whether bosentan, an ET receptor blocker, can reverse cardiac and vascular impairments in diabetic models. The researchers propose that altered ET-1 signaling may be a key factor in diabetic cardiovascular dysfunction. The study focuses on both heart function and vascular reactivity. The goal is to determine if ET receptor blockade can normalize these parameters in diabetic rats. This could provide insights into potential therapeutic strategies for diabetic cardiovascular complications.

Main Methods:

The study used a rat model of diabetes induced by streptozotocin (STZ). Four groups were established: control, control bosentan-treated, diabetic, and diabetic bosentan-treated. Cardiac function was assessed using an ex vivo working heart model. Parameters measured included rate of contraction (+dP/dt), rate of relaxation (-dP/dt), and left ventricular developed pressure (LVDP). Vascular reactivity was tested in isolated superior mesenteric arteries by measuring contractile responses to ET-1. Immunohistochemistry was used to detect ET-1-like immunoreactivity in heart and vascular tissues. The study design allowed for comparisons between treated and untreated groups. The model enabled direct assessment of both cardiac and vascular effects of ET receptor blockade. The methods focused on functional and immunological outcomes rather than biochemical markers. The approach combined physiological measurements with histological analysis.

Main Results:

Cardiac function was significantly reduced in untreated diabetic rats compared to controls. Bosentan treatment improved heart function in diabetic rats, as indicated by increased left ventricular developed pressure (LVDP) and improved rate of relaxation (-dP/dt). Vascular reactivity was also impaired in untreated diabetic rats, with exaggerated contractile responses to ET-1. Chronic bosentan treatment normalized these responses in diabetic rats. Immunohistochemical analysis revealed elevated ET-1-like immunoreactivity in both heart and vascular tissues of untreated diabetic rats. These findings suggest that ET-1 contributes to diabetic cardiovascular dysfunction. The data support the hypothesis that ET receptor blockade can reverse these impairments. The strongest evidence comes from the normalization of both cardiac and vascular parameters following bosentan treatment. The study also showed that ET-1 signaling is upregulated in diabetic tissues.

Conclusions:

The authors conclude that chronic ET receptor blockade with bosentan improves cardiovascular function in diabetic rats. Their findings suggest that altered ET-1 signaling contributes to diabetic cardiovascular dysfunction. The study supports the potential therapeutic role of ET receptor blockers in managing diabetic complications. The authors propose that ET-1 may be a key mediator of these impairments. The data do not establish ET-1 as the sole cause but suggest a significant contribution. The conclusions are based on observed improvements in both heart and vascular function. The study does not claim that ET receptor blockade is essential but suggests it may be beneficial. The findings are specific to the rat model and may not generalize to human diabetes.

The authors propose that altered ET-1 signaling contributes to diabetic cardiovascular complications.